Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.51 |
| ▸ | ST14 | Q9Y5Y6 | 3/20 | 0.45 |
| ▸ | SETD7 | Q8WTS6 | 3/20 | 0.45 |
| ▸ | BRS3 | P32247 | 2/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.45 |
| ▸ | MLNR | O43193 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | MLN | P12872 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 8/20 | 0.43 |
| ▸ | F10 | P00742 | 2/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | HPN | P05981 | 1/20 | 0.41 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13221516 | 1.00 | CACNA1B (0.51) | CACNA1BCYP3A4NR1I2ST14SETD7 | |
| SCHEMBL13221542 | 0.93 | CYP3A4 (0.49) | CACNA1BCYP3A4NR1I2ST14SETD7 | |
| SCHEMBL15103528 | 0.93 | CYP3A4 (0.49) | CACNA1BCYP3A4NR1I2ST14SETD7 | |
| SCHEMBL3136630 | 0.92 | CACNA1B (0.54) | CACNA1BCYP3A4NR1I2ST14SETD7 | |
| SCHEMBL13221503 | 0.92 | CACNA1B (0.54) | CACNA1BCYP3A4NR1I2ST14SETD7 | |
| SCHEMBL3040534 | 0.91 | CACNA1B (0.47) | CACNA1BCYP3A4NR1I2ST14SETD7 | |
| SCHEMBL3041120 | 0.85 | CACNA1B (0.53) | CACNA1BCYP3A4NR1I2F2KMT2A | |
| SCHEMBL13221467 | 0.85 | KMT2A (0.55) | CACNA1BCYP3A4NR1I2KMT2A | |
| SCHEMBL3042698 | 0.85 | CACNA1B (0.56) | CACNA1BCYP3A4NR1I2SMYD3KMT2A | |
| SCHEMBL3035933 | 0.85 | CACNA1B (0.56) | CACNA1BCYP3A4NR1I2SMYD3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205083-B1 | Substituted aryl sulfone derivatives as calcium channel blockers | MERCK SHARP & DOHME (US) | 2013-07-17 | — | — | EP | claimed |
| US-8304434-B2 | Substituted aryl sulfone derivatives as calcium channel blockers | MERCK SHARP & DOHME CORP. (US) | 2012-11-06 | — | — | US | claimed |
| US-20100210620-A1 | Substituted Aryl Sulfone Derivatives as Calcium Channel Blockers | SCHERING CORPORATION | 2010-08-19 | — | — | US | claimed |
| EP-2205083-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Merck Sharp & Dohme Corp. (US) | 2010-07-14 | — | — | EP | claimed |
| WO-2009045382-A1 | SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2009-04-09 | — | — | WO | claimed |
| EP-2205083-B1 | Substituted aryl sulfone derivatives as calcium channel blockers | MERCK SHARP & DOHME (US) | 2013-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210620-A1 | Substituted Aryl Sulfone Derivatives as Calcium Channel Blockers | TRPV1, TRPA1, CACNA1D | CACNA1B 23/4885CYP3A4 939/4885NR1I2 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.